Torrent Pharma Q2 FY27: Revenue Surges 51% But Net Profit Falls 9.6%, Misses Estimates

The Quick Take

• Torrent Pharma Q2 FY27 net profit fell 9.6% YoY to ₹534 crore, missing consensus estimates despite strong top-line growth.
• Revenue surged 50.8% to ₹4,979 crore, driven by branded generic product launches and geographic expansion.
• EBITDA rose 54.1% to ₹1,583 crore with margin improving to 32.33%, signaling operational leverage in core business.

Torrent Pharmaceuticals delivered a revenue surge in Q2 FY27, with 50.8% growth to ₹4,979 crore driven by its branded generics portfolio in India and key international markets. The company's EBITDA margin expanded meaningfully to 32.33%, reflecting better product mix and operational efficiency gains. However, net profit declined 9.6% year-on-year to ₹534 crore, a result that fell short of market expectations and points to elevated below-the-line costs — likely higher depreciation, interest expense, or exceptional items — offsetting the impressive operating performance across the quarter.

The mismatch between revenue growth and profit decline creates a mixed signal for Torrent's investor base. While EBITDA expansion confirms the core business is gaining scale, the earnings miss will likely pressure the stock near-term as sell-side models reprice downward. Peers in the Indian specialty pharma space — including Sun Pharma, Cipla, and Dr. Reddy's — will be benchmarked against Torrent's margin trajectory. The 32.33% EBITDA margin is healthy but the profit shortfall questions whether the revenue growth is fully translating to sustainable shareholder returns over subsequent quarters.

Investors should watch Torrent's Q3 FY27 guidance for clarity on the below-EBITDA cost drivers that compressed net profit despite strong revenue. Key indicators include whether higher depreciation stems from recent capital expenditure cycles that will moderate, or whether ongoing acquisitions are adding structural overhead. The macro variable is India's branded generics market growth — sustained healthcare spending and chronic disease penetration underpin Torrent's domestic portfolio. US FDA and European approvals for new product filings will determine whether the top-line momentum can sustain through FY28 and justify the current valuation multiple.

Synthesized from 1 source.